Search Results
Your search for ,WhO matches 21059 pages
Showing 8601 - 8650Quantitative Microelastography for Tumor Detection in Breast-Conserving Surgical Margins
A high-resolution, three-dimensional imaging technique, when combined with quantitative measurement of tissue elasticity, could accurately detect cancer within the resected margins of surgical specimens taken from patients undergoing breast-conserving surgery, according to a study published by...
PSA Dynamics and Response to Androgen-Deprivation Therapy
Adaptive treatments based on evolutionary principles may be an effective approach to prostate cancer treatment by preventing the development of drug resistance and prolonging patient survival. In an article in Nature Communications, Brady-Nicholls et al provided a closer look at a model and data...
A Segregated-Team Workflow Model During the COVID-19 Pandemic in a Cancer Center
In an article published in Annals of Oncology, members of the National University Cancer Institute of Singapore (NCIS) workflow team described a segregated-team workflow model that allowed continuation of cancer care at the comprehensive cancer center during the COVID-19 outbreak in Singapore....
FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
On April 17, the U.S. Food and Drug Administration (FDA) granted approval to tucatinib (Tukysa) in combination with trastuzumab/capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or...
Eduardo L. Cazap, MD, PhD, on COVID-19: The View From South America
Eduardo L. Cazap, MD, PhD, of the Sociedad Latinoamericana y del Caribe de Oncología Médica, and an international editor on The ASCO Post Editorial Board, talks about the situation in Argentina treating patients with COVID-19, and the 10-country research effort led by the World Health Organization...
FDA Encourages Plasma Donation From Patients Who Have Recovered From COVID-19, Collaborates to Produce Supplies for Testing
This week, the U.S. Food and Drug Administration (FDA) issued a statement encouraging patients who have fully recovered from COVID-19 for at least 2 weeks to donate plasma, in order to ramp up supply of convalescent plasma for treatment of infected individuals. The agency also announced that spun...
Pooled Meta-Analysis of Cancer Prevalence in Patients With COVID-19 Infection
In a meta-analysis reported in JCO Global Oncology, Desai et al found a pooled prevalence of cancer of 2.0% among patients with COVID-19 infection. Key Findings A literature search identified 11 reports providing data on prevalence of cancer in patients with COVID-19 infection. The overall...
Addition of Pembrolizumab to Docetaxel for Previously Treated Immunotherapy-Naive Patients With Advanced NSCLC
In the single-institution phase II PROLUNG trial reported in JAMA Oncology, Arrieta et al found that the addition of pembrolizumab to docetaxel improved objective response rate and progression-free survival in immunotherapy-naive patients with advanced non–small cell lung cancer (NSCLC) who...
Aspirin Use and Risk of Cancers of the Digestive Tract
Aspirin may be associated with a reduction in the risk of developing several cancers of the digestive tract. The largest and most comprehensive analysis to date of the link between aspirin and digestive tract cancers, published by Bosetti et al in Annals of Oncology, found reductions in the risk of ...
Practical Approach to Management of Patients With Cancer During the COVID-19 Pandemic: An International Collaborative Group Statement
In an article published in The Oncologist, an international collaborative group outlined issues and potential management approaches for the treatment of patients with cancer during the COVID-19 pandemic. Key issues facing cancer treatment and some of the potential measures for addressing these...
Patterns in Physician Use of Extended-Fraction Radiation Therapy for Bone Metastases
Routine use of extended-fraction radiation therapy—defined as more than 10 fractions—for the palliative treatment of bone metastases is considered a low-value intervention by the American Society for Radiation Oncology. In a retrospective cohort study reported in JCO Oncology Practice, Gupta et al...
FDA Approves Mitomycin Gel for Low-Grade Upper Tract Urothelial Cancer
On April 15, the U.S. Food and Drug Administration (FDA) approved mitomycin (Jelmyto) for adult patients with low-grade upper tract urothelial cancer. OLYMPUS Trial Efficacy determination was based on OLYMPUS, an ongoing, single-arm, multicenter trial enrolling 71 patients with treatment-naive or...
Joint Publication Focuses on Clinical Practice Guidelines on Opioid Use for Pain Management
A recently published article by Schatz et al offers new clarity around the use of prescription opioids in pain management for people with a diagnosis or history of cancer and chronic pain. The joint publication, which appeared in both JNCCN—Journal of the National Comprehensive Cancer Network and...
Neoadjuvant Immunotherapy in Early-Stage Colon Cancer
Patients with localized colon cancer may benefit from a short course of neoadjuvant immunotherapy, according to findings from the exploratory phase II NICHE study published by Myriam Chalabi, MD, and colleagues in Nature Medicine. Study Results Forty patients with two colon cancer subtypes—either ...
ASCO Releases New Guidance on Allocation of Limited Resources in the Oncology Community During COVID-19 Pandemic
ASCO has released a set of recommendations to support the oncology community as health-care institutions across the United States face potentially difficult decisions around the allocation of scarce health-care resources during the COVID-19 pandemic. In some geographic areas, the ongoing crisis is...
FDA Pipeline: Priority Reviews for Immunotherapy Based on Biomarker Status, Combination First-Line Therapy in Lung Cancer
Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to an immunotherapeutic agent for solid tumors with a high tumor mutational burden and to a combination treatment for the first-line treatment of metastatic or recurrent non–small cell lung cancer. The agency...
ASCO’s New COVID-19 Cancer Registry Aims to Understand Impact on Patients During Pandemic, Inform Future Care
On April 10, ASCO launched the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) to help the entire cancer community learn about the pattern of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 infections impact the delivery of cancer care and patient...
‘Textbook Outcome’ in Patients Undergoing Resection of Pancreatic Neuroendocrine Tumors
In a study reported in the Journal of Surgical Oncology, Timothy M. Pawlik, MD, MPH, PhD, and colleagues found that approximately half of patients undergoing resection of pancreatic neuroendocrine tumors (PNETs) had a “textbook outcome”—a result associated with significantly improved disease-free...
Outcomes of COVID-19 Infection in Patients With Cancer in Wuhan, China
In a retrospective cohort study reported in the Annals of Oncology, Li Zhang, MD, of the Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, and colleagues described characteristics and outcomes of COVID-19 infection in 28 patients with cancer from...
FDA Approves Selumetinib for Pediatric Patients With NF1 and Symptomatic Inoperable Plexiform Neurofibromas
On April 10, the U.S. Food and Drug Administration (FDA) approved selumetinib (Koselugo) for pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic inoperable plexiform neurofibromas. Selumetinib, a kinase inhibitor, is the first therapy approved for...
R. Kate Kelley, MD: Breakthroughs for Hepatocellular Carcinoma
At the University of California, San Francisco School of Medicine, R. Kate Kelley, MD, contributes to research focused on improving outcomes for patients with hepatocellular carcinoma. The trial: This was a phase III study that included 707 patients who received sorafenib and had disease...
From a Single Course, a Far-Reaching Impact Across the Region
It was a great honor for the Russian Society of Clinical Oncology (RUSSCO) to collaborate on the ASCO IPCW, and for me to be a co-organizer of the event from the Russian side. RUSSCO is a professional cancer society with the mission to advance cancer treatment and cures. The organization...
International Palliative Care Workshop in Russia Educates Providers, Improves Care Across Region
ASCO, in collaboration with international oncology societies, hosts International Palliative Care Workshops (IPCWs) designed to teach participants practical skills in patient communication and the management of cancer symptoms and pain. The IPCWs are led by ASCO member volunteers and local experts...
Living A Full Life After Pancreatic Cancer
I have been a radiologic technologist for 47 years, so after going to the bathroom one Sunday morning in October 2018 and finding my urine had suddenly turned dark, I knew something was wrong. I wasn’t in any pain and did not have a urinary tract infection, which would explain the discoloration of...
City of Hope Deploys Platform, Makes Study Data Accessible
A $12 million federal grant enabled City of Hope and collaborators to deploy a novel cloud-computing platform, making an immense amount of data from a historic 25-year study more accessible and user-friendly. The ongoing California Teachers Study, which began in 1995, has already given researchers...
A Hallmark Moment
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
What’s in a Name?
When Narjust Duma, MD, Assistant Professor of Medicine and a thoracic oncologist at the University of Wisconsin Carbone Cancer Center in Madison, presented the findings from her study, “Evaluating Unconscious Bias During Speaker Introductions at an International Oncology Conference,” during the...
Using Respectful Language to Reduce Unconscious Bias in Oncology Care
An abstract presented at the 2019 ASCO Annual Meeting titled “Evaluating Unconscious Bias During Speaker Introductions at an International Oncology Conference,” by Narjust Duma, MD, Assistant Professor of Medicine and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center in...
Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held in Orlando, Florida, from February 19–23, 2020. The scientific program addressed the most timely issues in ...
Updates From Selected Clinical Trials in Breast Cancer
Each year, The ASCO Post asks Jame Abraham, MD, FACP, Chairman of the Department of Hematology and Medical Oncology at Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, to offer his picks for the most important research presented at 2019 San...
Inspired by Her Physician Father, Reshma Jagsi, MD, DPhil, Tirelessly Advocates for Women’s Health and Careers in Medicine
Physician-scientist, Reshma Jagsi, MD, DPhil, was encouraged by her parents to become a politically active, socially conscious citizen of the world. “As a young woman, my mother traveled from Africa on a scholarship to the United States, where she attended the University of Wisconsin. It was in the ...
SEMA4D Inhibition: A Novel Means of Improving Immune Response
A novel class of inhibitors may hold some promise for boosting responses to checkpoint inhibitors and for sensitizing poorly immunogenic tumors, such as pancreatic cancer, to immunotherapy. The drug targets semaphorin 4D (SEMA4D), a glycoprotein expressed on the cell membranes of many tumor types....
Expert Point of View: Jarushka Naidoo, MBBCh
Discussant of the abstract on antibiotic exposure, Jarushka Naidoo, MBBCh, Assistant Professor of Oncology and Attending Physician at the Sidney Kimmel Cancer Center at Johns Hopkins University, said that Mr. Chu and colleagues have added to the recent literature examining concurrent use of...
Prior Antibiotic Use Linked to Poorer Survival in Patients With Advanced Melanoma Receiving Immune Checkpoint Inhibitors
Treatment with antibiotics prior to immune checkpoint inhibitor therapy may confer poorer overall survival and an increased risk of colitis in patients with advanced melanoma, according to data presented at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.1 The largest institutional...
Should Restrictions on Genetic Testing Be Loosened?
The loosening of restrictions on genetic testing would mean that all health-care providers could help move this needle to where it should be, according to Kevin S. Hughes, MD, a surgeon at Massachusetts General Hospital, Professor of Surgery at Harvard Medical School, and Medical Director of the...
Pembrolizumab Plus Radiotherapy Worthy of Further Study in Locally Advanced Squamous Cell Head and Neck Cancer
The combination of the checkpoint inhibitor pembrolizumab and definitive radiation therapy appears to be a safe and feasible option for patients with locally advanced head and neck cancer who are not eligible for cisplatin, according to data presented at the 2020 Multidisciplinary Head and Neck...
Expert Point of View: Tanguy Y. Seiwert, MD
Moderator of the session, Tanguy Y. Seiwert, MD, Director of the Head and Neck Cancer Oncology Disease Group and Assistant Professor of Oncology at Johns Hopkins University, in Baltimore, underscored the “dramatically good” preclinical data supporting the use of mTOR inhibitors in advanced...
Study Suggests Adjuvant Everolimus May Benefit Patients With Advanced Head and Neck Cancer
The mTOR inhibitor everolimus, used to treat breast and kidney cancers, may benefit patients with advanced squamous cell carcinoma of the head and neck, according to data presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium.1 The results of an investigator-initiated, phase II...
ASCO Releases Resource-Stratified Guideline on the Treatment of Late-Stage Colorectal Cancer
ASCO has released a new guideline for clinicians and policymakers in resource-constrained settings on treating patients with late-stage colorectal cancer.1 “Around the world, there is a huge variation in resources, and what is available to clinicians may change week to week,” said Mary D....
Immunotherapy ‘Comes of Age’ in Breast Cancer
Immunotherapeutics in breast cancer will likely not be limited to late-stage triple-negative breast cancer. Earlier lines, combination regimens, and expansion into different disease subtypes should become part of this emerging landscape, according to Hope S. Rugo, MD, FASCO, Professor of Medicine...
T-Cell Responses and Benefit From Treatment With Ipilimumab in Patients With Metastatic Castration-Resistant Prostate Cancer
Although patients with metastatic castration-resistant prostate cancer typically have limited responses to immunotherapy, a subset of patients with pretreatment evidence of active T-cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a phase II...
New Prognostic Score for Asymptomatic Patients With Early-Stage CLL
A new prognostic tool may help to predict time to first treatment for patients with early-stage, asymptomatic chronic lymphocytic leukemia (CLL). Researchers described what they hope will become a point-of-care resource to help improve clinical decision-making in a study published by Rossi et al in ...
Factors Associated With Early Readmissions to Hospital Oncology Services
In a study reported in JCO Oncology Practice, Zibelli et al found that patients with cancer readmitted to hospital within 30 days from index admission often made the decision to return to hospital themselves, without input from their care teams. Study Details The study included 33 patients...
Brief Highlights on Novel Therapies for Prostate, Bladder, and Kidney Cancers
Attendees gathered at the 2020 Genitourinary Cancers Symposium in San Francisco to hear the latest news about treating patients with cancers of the prostate, bladder, kidneys, and testicles. In addition to the comprehensive coverage of the meeting in The ASCO Post, here are some brief highlights...
Pediatric Cancer Investment Needs and Benefits: Findings From a Commission Created by The Lancet Oncology
Improving care for children with cancer worldwide could bring a triple return on investment and prevent millions of deaths, according to a new Commission report published by Atun et al in The Lancet Oncology. Without additional investment in childhood cancer care, new estimates produced for the...
Stereotactic Ablative Radiation vs Observation in Oligometastatic Prostate Cancer: ORIOLE Trial
In a phase II trial reported in JAMA Oncology, Phillips et al found that stereotactic ablative radiotherapy (SABR) was associated with improved outcomes vs observation in men with oligometastatic prostate cancer. The benefit was augmented in patients with total consolidation of disease identified...
Case Study: Patient With Multiple Myeloma Treated for COVID-19 With Tocilizumab
A case study of one patient with multiple myeloma diagnosed with COVID-19 in Wuhan, China, published by Zhang et al in Blood Advances examined the efficacy of the immunosuppressant tocilizumab as a treatment for this particular patient. The report also suggested that patients with hematologic...
$20 Million in Grants Awarded to Identify Therapies for COVID-19
The partners in the COVID-19 Therapeutics Accelerator—a large-scale initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard—awarded $20 million in initial grants to three institutions. The University of Washington, the University of Oxford, and La Jolla Institute...
Treatment With Checkpoint Inhibitors May Cause Thyroid Dysfunction
Thyroid dysfunction following treatment with immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting (Abstract SAT-418), and that will be published in Journal of the Endocrine...
Daratumumab for Relapsed or Refractory Multiple Myeloma: Subcutaneous vs Intravenous Dosing
Findings from the phase III COLUMBA trial have shown that subcutaneous daratumumab is not inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in patients with relapsed or refractory multiple myeloma. These results were published by...
